{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:54:18Z","timestamp":1787727258102,"version":"build-2784847793"},"reference-count":35,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.ijpharm.2015.05.062","type":"journal-article","created":{"date-parts":[[2015,6,7]],"date-time":"2015-06-07T07:53:06Z","timestamp":1433663586000},"page":"69-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Innovative approach in Pompe disease therapy: Induction of immune tolerance by antigen-encapsulated red blood cells"],"prefix":"10.1016","volume":"491","author":[{"given":"Magali","family":"Cremel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Campello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quitterie","family":"Barthe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willy","family":"Berlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Horand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Godfrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2015.05.062_bib0005","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0010","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/eci.12.40","article-title":"Immune modulation in Pompe disease treated with enzyme replacement therapy","volume":"8","author":"Banugaria","year":"2012","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0015","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/gim.2012.110","article-title":"Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease","volume":"15","author":"Banugaria","year":"2013","journal-title":"Genet. Med."},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0020","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1212\/WNL.0b013e3182a6cb4b","article-title":"Clinical and biochemical improvements in a patient with MNGIE following enzyme replacement","volume":"81","author":"Bax","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0025","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1016\/j.vaccine.2010.02.013","article-title":"In situ targeting of dendritic cells by antigen-loaded red blood cells: a novel approach to cancer immunotherapy","volume":"28","author":"Banz","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0030","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/hep.23043","article-title":"Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver","volume":"50","author":"Breous","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0035","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF00926740","article-title":"Modulated red blood cell survival by membrane protein clustering","volume":"144","author":"Chiarantini","year":"1995","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0040","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijpharm.2012.12.044","article-title":"Red blood cells as innovative antigen carrier to induce specific immune tolerance","volume":"443","author":"Cremel","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0045","doi-asserted-by":"crossref","first-page":"419692","DOI":"10.1155\/2013\/419692","article-title":"Liver transplant tolerance and its application to the clinic: can we exploit the high dose effect?","volume":"2013","author":"Cunningham","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0050","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ymgme.2010.08.009","article-title":"High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa","volume":"101","author":"de Vries","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0055","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2141.2011.08588.x","article-title":"L-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial","volume":"153","author":"Domenech","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0060","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/hep.25498","article-title":"Dendritic cells take on more tasks in the liver","volume":"55","author":"Duffield","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0065","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jpeds.2013.03.002","article-title":"B-cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease","volume":"163","author":"Elder","year":"2013","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0070","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1517\/14712598.2012.631909","article-title":"International seminar on the red blood cells as vehicles for drugs","volume":"12","author":"Godfrin","year":"2012","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0075","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1006\/exmp.1999.2290","article-title":"Mechanisms of suppression of experimental autoimmune encephalomyelitis by intravenous administration of myelin basic protein: role of regulatory spleen cells","volume":"68","author":"Hilliard","year":"2000","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0080","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4049\/jimmunol.176.1.441","article-title":"Interaction of mouse dendritic cells and malaria-infected erythrocytes: uptake, maturation, and antigen presentation","volume":"176","author":"Ing","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0085","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0304-4165(96)00040-2","article-title":"Targeting of mouse erythrocytes by band 3 crosslinkers","volume":"1291","author":"Jordan","year":"1996","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0090","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0095","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1053\/j.gastro.2013.12.036","article-title":"Hepatic immune regulation and its involvement in viral hepatitis infection","volume":"146","author":"Knolle","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0100","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2174\/156652309790031094","article-title":"Immunomodulatory gene therapy in lysosomal storage disorders","volume":"9","author":"Koeberl","year":"2009","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0105","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jim.2008.02.005","article-title":"Three-colour fluorescence immunohistochemistry reveals the diversity of cells staining for macrophage markers in murine spleen and liver","volume":"334","author":"Lloyd","year":"2008","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0110","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genet. Med."},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0115","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1172\/JCI200316887","article-title":"Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer","volume":"111","author":"Mingozzi","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0120","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1517\/17425241003610633","article-title":"Drug delivery by red blood cells: vascular carriers designed by mother nature","volume":"7","author":"Muzykantov","year":"2010","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0125","doi-asserted-by":"crossref","first-page":"e98336","DOI":"10.1371\/journal.pone.0098336","article-title":"Immune responses and hypercoagulation in ERT for Pompe disease are mutation and rhGAA dose dependent","volume":"9","author":"Nayak","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0130","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3324\/haematol.2014.112821","article-title":"Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity","volume":"100","author":"Oldenburg","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0135","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ymgme.2012.04.027","article-title":"The impact of antibodies in late-onset Pompe disease: a case series and literature review","volume":"106","author":"Patel","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0140","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/00007890-199305000-00041","article-title":"Lymphocyte suppression by Kupffer cells prevents portal venous tolerance induction: a study of macrophage function after intravenous gadolinium","volume":"55","author":"Roland","year":"1993","journal-title":"Transplantation"},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0145","first-page":"2641","article-title":"Immunomodulation of experimental autoimmune uveoretinitis by intravenous injection of uveitogenic peptides","volume":"33","author":"Sasamoto","year":"1992","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0150","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/mt.2009.195","article-title":"Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease","volume":"18","author":"Sun","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0155","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/eji.201343840","article-title":"The amount of self-antigen determines the effector function of murine T cells escaping negative selection","volume":"44","author":"Swee","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0160","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nri2858","article-title":"Antigen-presenting cell function in the tolerogenic liver environment","volume":"10","author":"Thomson","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0165","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1517\/17425247.2014.880422","article-title":"Carrier erythrocytes: recent advances, present status, current trends and future horizons","volume":"11","author":"Zarrin","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0170","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ymthe.2003.11.015","article-title":"AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice","volume":"9","author":"Ziegler","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ijpharm.2015.05.062_bib0175","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1073\/pnas.86.6.2040","article-title":"Encapsulation of doxorubicin in liver-targeted erythrocytes increases the therapeutic index of the drug in a murine metastatic model","volume":"86","author":"Zocchi","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U.S.A."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517315004901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517315004901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T01:27:08Z","timestamp":1537579628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517315004901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":35,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0378517315004901"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2015.05.062","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovative approach in Pompe disease therapy: Induction of immune tolerance by antigen-encapsulated red blood cells","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2015.05.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}